

Clinical Trial Protocol

Iranian Registry of Clinical Trials

02 Aug 2026

Safety and efficacy comparison of gel and emulgel formulations of tretinoin 0.025% and clindamycin 1.2% for treatment of mild to moderate acne vulgaris

Protocol summary

Study aim

Safety and efficacy comparison of gel and emulgel formulations of tretinoin 0.025% and clindamycin 1.2% for treatment of mild to moderate acne vulgaris

Design

The study is a phase 2, parallel treatment-control clinical trial. Sample size is 20. The study is randomized and double blinded. Randomization is done simply using a blind card, so names of the formulations are written on the same cards then each card is randomly selected for any side of the face.

Settings and conduct

The study will be performed in Center for the Study and Research of Diseases of the Skin and Leprosy, 20 volunteers with acne vulgaris will be selected and enrolled in the study after signing consent form. Volunteers will be taught to use " of Tretinoin 0.025% and Clindamycin 1.2% for 8 weeks once in a day. Before intervention and at the end of 4 and 8 weeks later changing in skin will be measured. This study is double blinded. The clinicians who performed the clinical assessments and objective device analysis are completely blinded to the treatment type. Participants will receive the treatment according to the randomization list by an independent assistant.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Male or female aged 16-40 years, Mild to moderate inflammatory or non-inflammatory acne lesions (grade 1 to 3 according to the table) on face
Exclusion criteria: People with allergies to formulation ingredients, Nodular or cystic lesions that represent a severe type of acne vulgaris

Intervention groups

Intervention group: Topical use of emulgel formulations of tretinoin 0.025% and clindamycin 1.2% for 8 weeks once in a day
Control group: Topical use of gel formulations of tretinoin 0.025% and clindamycin 1.2%

for 8 weeks once in a day

Main outcome variables

Evaluate of acne severity index by a physician

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20150101020514N13**

Registration date: **2021-12-13, 1400/09/22**

Registration timing: **prospective**

Last update: **2021-12-13, 1400/09/22**

Update count: **0**

Registration date

2021-12-13, 1400/09/22

Registrant information

Name

Alireza Firooz

Name of organization / entity

Tehran University of Medical Science

Country

Iran (Islamic Republic of)

Phone

+98 21 8897 8190

Email address

firozali@tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-12-22, 1400/10/01

Expected recruitment end date

2022-10-23, 1401/08/01

Actual recruitment start date

empty
Actual recruitment end date
empty
Trial completion date
empty

Scientific title
Safety and efficacy comparison of gel and emulgel formulations of tretinoin 0.025% and clindamycin 1.2% for treatment of mild to moderate acne vulgaris

Public title
Safety and efficacy comparison of gel and emulgel formulations of Tertinoin and Clindamycin for treatment of mild to moderate acne vulgaris

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Male or female aged 16-40 years Mild to moderate inflammatory or non-inflammatory acne lesions (grade 1 to 3 according to the table) on face
Exclusion criteria:
People with allergies to formulation ingredients Nodular or cystic lesions that represent a severe type of acne vulgaris

Age
From **16 years** old to **40 years** old

Gender
Both

Phase
2

Groups that have been masked

- Participant
- Investigator

Sample size
Target sample size: **20**

Randomization (investigator's opinion)
Randomized

Randomization description
Randomization is done simply using a blind card, so names of the formulations are written on the same cards then each card is randomly selected for any side of the face

Blinding (investigator's opinion)
Double blinded

Blinding description
Products of both groups are packed in similar boxes with different numeric code. In case of assessor blinding, the randomization list is given to a third person. The clinicians who performed the clinical assessments and objective device analysis are completely blinded to the treatment type. participants will receive the treatment according to the randomization list by an independent assistant.

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Tehran University of Medical Sciences

Street address

Room 105 , 5th floor, Central construction of Tehran University of Medical Sciences, Ghods intersection, Keshavarz blvd.

City

Tehran

Province

Tehran

Postal code

1417653761

Approval date

2021-05-31, 1400/03/10

Ethics committee reference number

IR.TUMS.MEDICINE.REC.1400.199

Health conditions studied

1

Description of health condition studied

Acne vulgaris

ICD-10 code

L70.0

ICD-10 code description

Acne vulgaris

Primary outcomes

1

Description

Evaluate the improvement of acne severity index by a physician

Timepoint

Before intervention, 4 and 8 weeks after the start of use

Method of measurement

An independent dermatologists perform evaluation and scoring with the help of photos based on the percentage of improvement in acne using:(0=normal skin, 2=skin is almost clear, 3=some non-inflammatory lesions are present, 4=non-inflammatory lesions are predominant, with multiple inflammatory lesions. 5=highly inflammatory lesions predominate)

Secondary outcomes

1

Description

Trans Epidermal Water Loss

Timepoint

Before intervention, 4 and 8 weeks after the start of use

Method of measurement

Tewameter

2**Description**

Skin sebum

Timepoint

Before intervention, 4 and 8 weeks after the start of use

Method of measurement

Sebumeter

Intervention groups**1****Description**

Intervention group: Topical application of compounding emulgel (not industrial) containing tretinoin 0.025% and clindamycin 1.2% on acne lesions of one side of the face (randomly) once a day (before sleeping), for 8 weeks

Category

Treatment - Drugs

2**Description**

Control group: Topical application of compounding gel (not industrial) containing tretinoin 0.025% and clindamycin 1.2% on acne lesions of one side of the face (randomly) once a day (before sleeping), for 8 weeks

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Center for research and training in skin diseases and leprosy

Full name of responsible person

Aniseh Samadi

Street address

No. 415, Shahid Naderi (Soheil) Street, Taleqani Avenue

City

Tehran

Province

Tehran

Postal code

1416613675

Phone

+98 21 8897 0658

Email

dermalab@tums.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Jarf Andishan Nnavid Salamat knowlage based company (JANUS)

Full name of responsible person

Saman Ahmad Nasrollahi

Street address

No. 415, Shahid Naderi (Soheil) Street, Taleqani Avenue

City

Tehran

Province

Tehran

Postal code

1416613675

Phone

+98 21 8896 2981

Email

headoffice@januspharma.com

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Jarf Andishan Nnavid Salamat knowlage based company (JANUS)

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Persons

Person responsible for general inquiries**Contact****Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

Aniseh Samadi

Position

Manger of clinical study unit

Latest degree

Ph.D.

Other areas of specialty/work

Skin Biometrics

Street address

No. 415, Shahid Naderi (Soheil) Street, Taleqani Avenue

City

Tehran

Province

Tehran
Postal code
1416613675
Phone
+98 21 8896 0880
Email
aniseh_samadi@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Alireza Firooz
Position
Professor of dermatology
Latest degree
Specialist
Other areas of specialty/work
Dermatology
Street address
No. 415, Taleqani Avenue
City
Tehran
Province
Tehran
Postal code
1416613675
Phone
+98 21 8897 2220
Email
firozali@tums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Tehran University of Medical Sciences

Full name of responsible person
Maryam Ahmadi
Position
Researcher
Latest degree
Master
Other areas of specialty/work
Clinical trial
Street address
No 415, Taleqani Street
City
Tehran
Province
Tehran
Postal code
1416613675
Phone
+98 21 8897 2220
Email
dermalab@tums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Not applicable

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Not applicable

Data Dictionary

Not applicable